Suppr超能文献

透析报销:七个国家的比较。

Reimbursement of dialysis: a comparison of seven countries.

机构信息

Nephrology Section, University Hospital, De Pintelaan 185, B9000 Ghent, Belgium.

出版信息

J Am Soc Nephrol. 2012 Aug;23(8):1291-8. doi: 10.1681/ASN.2011111094. Epub 2012 Jun 7.

Abstract

Reimbursement for chronic dialysis consumes a substantial portion of healthcare costs for a relatively small proportion of the total population. Each country has a unique reimbursement system that attempts to control rising costs. Thus, comparing the reimbursement systems between countries might be helpful to find solutions to minimize costs to society without jeopardizing quality of treatment and outcomes. We conducted a survey of seven countries to compare crude reimbursement for various dialysis modalities and evaluated additional factors, such as inclusion of drugs or physician payments in the reimbursement package, adjustment in rates for specific patient subgroups, and pay for performance therapeutic thresholds. The comparison examines the United States, the province of Ontario in Canada, and five European countries (Belgium, France, Germany, The Netherlands, and the United Kingdom). Important differences between countries exist, resulting in as much as a 3.3-fold difference between highest and lowest reimbursement rates for chronic hemodialysis. Differences persist even when our data were adjusted for per capita gross domestic product. Reimbursement for peritoneal dialysis is lower in most countries except Germany and the United States. The United Kingdom is the only country that has implemented an incentive if patients use an arteriovenous fistula. Although home hemodialysis (prolonged or daily dialysis) allows greater flexibility and better patient outcomes, reimbursement is only incentivized in The Netherlands. Unfortunately, it is not yet clear that such differences save money or improve quality of care. Future research should focus on directly testing both outcomes.

摘要

慢性透析治疗的报销费用占总人口中相对较小比例的医疗保健费用的很大一部分。每个国家都有独特的报销系统,试图控制成本的上升。因此,比较各国之间的报销制度可能有助于找到解决方案,在不影响治疗质量和结果的情况下,将社会成本降至最低。我们对七个国家进行了调查,比较了各种透析方式的粗略报销情况,并评估了其他因素,如在报销套餐中纳入药物或医生薪酬、对特定患者亚组的费率进行调整、以及根据治疗效果设定支付阈值。比较研究涵盖了美国、加拿大安大略省和五个欧洲国家(比利时、法国、德国、荷兰和英国)。国家之间存在重要差异,导致慢性血液透析的最高和最低报销率之间相差高达 3.3 倍。即使我们根据人均国内生产总值对数据进行了调整,差异仍然存在。除了德国和美国,大多数国家的腹膜透析报销都较低。英国是唯一一个对使用动静脉瘘的患者实施激励措施的国家。尽管家庭血液透析(延长或每日透析)可以提供更大的灵活性和更好的患者结果,但只有荷兰对其进行了报销激励。不幸的是,目前尚不清楚这些差异是否能节省成本或提高护理质量。未来的研究应重点直接测试这两个结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验